311 related articles for article (PubMed ID: 20079863)
1. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
Majhail NS; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863
[TBL] [Abstract][Full Text] [Related]
2. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.
Majhail NS; DeFor T; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2008 Jul; 14(7):790-4. PubMed ID: 18541198
[TBL] [Abstract][Full Text] [Related]
4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
5. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
[TBL] [Abstract][Full Text] [Related]
6. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Sivgin S; Eser B; Bahcebasi S; Kaynar L; Kurnaz F; Uzer E; Pala C; Deniz K; Ozturk A; Cetin M; Unal A
Ann Hematol; 2012 May; 91(5):743-749. PubMed ID: 22051904
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
[TBL] [Abstract][Full Text] [Related]
9. Iron overload in hematopoietic cell transplantation.
Majhail NS; Lazarus HM; Burns LJ
Bone Marrow Transplant; 2008 Jun; 41(12):997-1003. PubMed ID: 18438425
[TBL] [Abstract][Full Text] [Related]
10. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Vallejo C; Batlle M; Vázquez L; Solano C; Sampol A; Duarte R; Hernández D; López J; Rovira M; Jiménez S; Valcárcel D; Belloch V; Jiménez M; Jarque I;
Haematologica; 2014 Oct; 99(10):1632-7. PubMed ID: 24997153
[TBL] [Abstract][Full Text] [Related]
11. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation.
Sucak GT; Yegin ZA; Ozkurt ZN; Aki SZ; Yağci M
Transplant Proc; 2010 Jun; 42(5):1841-8. PubMed ID: 20620535
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
[TBL] [Abstract][Full Text] [Related]
13. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
[TBL] [Abstract][Full Text] [Related]
14. Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation.
Brissot E; Savani BN; Mohty M
Semin Hematol; 2012 Jan; 49(1):35-42. PubMed ID: 22221783
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Phatak P; Brissot P; Wurster M; Adams PC; Bonkovsky HL; Gross J; Malfertheiner P; McLaren GD; Niederau C; Piperno A; Powell LW; Russo MW; Stoelzel U; Stremmel W; Griffel L; Lynch N; Zhang Y; Pietrangelo A
Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.
Franchini M; Gandini G; Veneri D; de Matteis G; Federici F; Solero P; Aprili G
Transfusion; 2004 Jun; 44(6):833-7. PubMed ID: 15157247
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
18. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox use after hematopoietic stem cell transplantation in pediatric patients with beta-thalassemia major: preliminary results.
Unal S; Kuskonmaz B; Hazirolan T; Eldem G; Aytac S; Cetin M; Uckan D; Gumruk F
Pediatr Hematol Oncol; 2010 Sep; 27(6):482-9. PubMed ID: 20615065
[TBL] [Abstract][Full Text] [Related]
20. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.
Wermke M; Schmidt A; Middeke JM; Sockel K; von Bonin M; Schönefeldt C; Mair S; Plodeck V; Laniado M; Weiss G; Schetelig J; Ehninger G; Theurl I; Bornhäuser M; Platzbecker U
Clin Cancer Res; 2012 Dec; 18(23):6460-8. PubMed ID: 22991415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
